Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01314
|
|||||
| Drug Name |
Velpatasvir
|
|||||
| Synonyms |
GS 5816; GS-5816; GS5816; KCU0C7RS7Z; UNII-KCU0C7RS7Z; Velpatasvir; Velpatasvir [USAN:INN]; Verpatasvir; methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-4-yl}-1,11-dihydro[2]benzopyrano[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Hepatitis C virus infection [ICD11: 1E50.2, 1E51.1] | Phase 1 | [1] | |||
| Therapeutic Class |
Antiviral Agent
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C49H54N8O8
|
|||||
| Canonical SMILES |
CC1CCC(N1C(=O)C(C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)C8CC(CN8C(=O)C(C9=CC=CC=C9)NC(=O)OC)COC
|
|||||
| InChI |
InChI=1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)/t27-,28-,38-,39-,41-,42+/m0/s1
|
|||||
| InChIKey |
FHCUMDQMBHQXKK-CDIODLITSA-N
|
|||||
| CAS Number |
CAS 1377049-84-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 883 | Topological Polar Surface Area | 193 | ||
| Heavy Atom Count | 65 | Rotatable Bond Count | 13 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 10 | |||
| XLogP |
6.2
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:133009
|
|||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | ClinicalTrials.gov (NCT02002767) Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment | |||||
| 2 | Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.